Show simple item record

dc.contributor.authorSwofford, Brenen P.
dc.contributor.authorHomsi, Jade
dc.date.accessioned2019-11-08T22:26:04Z
dc.date.available2019-11-08T22:26:04Z
dc.date.issued2017
dc.identifier.citationSwofford, B. P., & Homsi, J. (2017). Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma. Case reports in oncological medicine, 2017.en_US
dc.identifier.issn2090-6714
dc.identifier.doi10.1155/2017/8241624
dc.identifier.urihttp://hdl.handle.net/10150/635143
dc.description.abstractMelanoma is a disease process which has been increasing in incidence over the past three decades and metastatic melanoma carries a poor prognosis. Through genetic studies of this disease, it has been determined that the BRAF V600 mutation plays a major role in the pathophysiology of the disease and this has led to the utilization of targeted therapy (BRAF and MEK inhibitors) in its treatment. Other BRAF mutations (non-V600 mutations) are rare in melanoma and targeted therapy is not indicated for patients with these mutations due to reduced response rates. An emerging option for metastatic melanoma with uncommon BRAF mutations is immunotherapy using checkpoint inhibitors such as PD-1 inhibitors or CTLA-4 inhibitors. Currently, it is unknown how patients with BRAF non-V600 mutations respond to immunotherapy. This report will examine the effect of immunotherapy on two distinct metastatic melanoma patients, each with uncommon BRAF mutations, occurring outside the V600 locus (E586K and G469E). These patients were noted to have a durable, complete response when treated with immunotherapy and continue to exhibit a response 9 and 15 months after discontinuing therapy. Further research and clinical trials are needed to study patients with uncommon BRAF mutations and the potential therapeutic benefit of immunotherapy.en_US
dc.language.isoenen_US
dc.publisherHINDAWI LTDen_US
dc.rights© 2017 Brenen P. Swofford and Jade Homsi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.titleUncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanomaen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Med Phoenixen_US
dc.identifier.journalCASE REPORTS IN ONCOLOGICAL MEDICINEen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.volume2017
dc.source.beginpage1-4
refterms.dateFOA2019-11-08T22:26:04Z


Files in this item

Thumbnail
Name:
8241624.pdf
Size:
2.463Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record